InspireMD (NYSE:NSPR) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

InspireMD (NYSE:NSPR - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06), Zacks reports. InspireMD had a negative net margin of 320.97% and a negative return on equity of 55.71%. The company had revenue of $1.51 million during the quarter, compared to analysts' expectations of $1.38 million. During the same quarter in the previous year, the business posted ($0.53) EPS.

InspireMD Stock Performance

NSPR stock traded down $0.08 during midday trading on Wednesday, reaching $2.30. 28,991 shares of the company were exchanged, compared to its average volume of 31,142. The company has a market cap of $53.82 million, a price-to-earnings ratio of -2.10 and a beta of 0.92. InspireMD has a 1-year low of $1.58 and a 1-year high of $3.85. The stock's 50-day simple moving average is $2.24 and its 200 day simple moving average is $2.56.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of InspireMD in a research report on Friday, May 10th. They issued a "sell" rating on the stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.